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Abstract  
Background: The development of urothelial malignancy is not solely a consequence of 
loss of proliferation constraints, but also involves loss of cellular differentiation, defined 
histopathologically as grade. Although tumour grade is an independent prognostic marker 
for urothelial carcinoma (UC), the molecular events underpinning the loss of urothelial 
differentiation are poorly understood.   
Objective: To examine the effect of gene alterations implicated in UC development on 
the ability of human urothelial cells to undergo molecular differentiation and form a 
functional urothelial barrier.  
Design, Setting, and Participants: Laboratory study.  
Intervention(s): Normal human urothelial (NHU) cell cultures were transduced with 
recombinant retroviruses to produce stable sub-lines over-expressing wild-type or 
oncogenic mutated FGFR3, or human telomerase (hTERT). Previously-generated NHU 
sublines carrying dominant-negative CDK4 and p53 mutant genes or immortalised with the 
human papillomavirus 16 E6 oncoprotein were included.   
Measurements: The activity of introduced transgenes was demonstrated by comparing 
phenotypes of transgene-expressing and isogenic control NHU cells. Modified and control 
sub-lines were compared for changes in generational potential (lifespan) and capacity to 
respond to differentiation-inducing signals by transcript expression of uroplakins 2 and 3. 
The ability to form a barrier epithelium was assessed by measuring the transepithelial 
electrical resistance. 
Results & Limitations: By contrast to tumour suppressor loss-of-function or oncogene 
over-activation, hTERT over-expression alone led to life-span extension and 
immortalisation. hTERT-immortalised cells carried no gross genomic alterations, but 
became progressively insensitive to differentiation signals and lost the ability to form an 
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epithelial barrier. Further characterisation of hTERT cells revealed a down-regulation of 
p16 cyclin-dependent kinase inhibitor expression and loss of responsiveness to peroxisome 
proliferator-activated receptor gamma, providing mechanistic explanations for the 
subjugation of senescence constraints and abrogation of differentiation capability, 
respectively.  Although immortalised urothelial cell lines without karyotypic aberrations 
may be generated, such cell lines are compromised in terms of differentiation and 
functional capacity.  
Conclusions: Over-expression of hTERT promotes development of an immortalised, 
differentiation-insensitive urothelial cell phenotype.  Whereas such cells offer a useful 
insight into the grade/stage paradigm of UC, they have limited value for investigating 
normal urothelial cell/tissue biology and physiology.  
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Introduction  
Bladder cancer is the fourth commonest cancer in men and arises predominantly as 
urothelial carcinoma (UC).  Clinical evidence has revealed two major pathways (reviewed 
in [1]).  Most UC are low-grade and recurrent, with low rates of malignant progression, 
whereas high-grade UC are associated with a high risk of progression to muscle invasive 
disease, with attendant poor prognosis. Carcinoma in-situ, a high-grade urothelial lesion 
representing ~10% of newly-diagnosed UC, is considered the principal precursor of 
muscle invasive disease.  Despite the clear association between grade and prognosis [2], 
current models of bladder carcinogenesis concentrate on the impact of molecular changes 
for tumour growth, rather than differentiation.  
 
The majority (>70%) of low-grade tumours exhibit activating mutations of Fibroblast 
Growth Factor Receptor 3 (FGFR3), compared to <20% of invasive tumours [3]. The most 
common mutation is a S249C substitution, which allows ligand-independent dimerisation 
and constitutive auto-phosphorylation. As a result, FGFR3 enhances proliferation by 
activating Ras-Raf-Extracellular signal-Related Kinase (ERK), Phosphatidylinositol 3-Kinase 
(PI3-K) and Signal Transducer and Activator of Transcription (STAT) proteins [4].  The 
p53/p21 and p16/Retinoblastoma (Rb) tumour suppressor pathways are frequently altered 
in muscle-invasive disease, with p53 loss associated with muscle-invasive disease and 
p16/Rb loss linked to tumours of higher metastatic potential (reviewed in [5]).  
 
A further failing of current models is the lack of inclusion of critical genes/proteins despite 
strong evidence for a role in cancer progression. Activation of telomerase reverse 
transcriptase (hTERT) occurs in >90% of cancers [6], including UC [7].  hTERT is 
expressed by stem cells, but repressed in most normal somatic cells where over-
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expression leads to immortalisation by overcoming senescence pathways.  This has 
contributed towards both supporting the concept of the cancer stem cell and recognising 
telomerase activation as a key-stage in cancer progression [8].   
 
We have developed methodologies to propagate normal human urothelial (NHU) cells as 
finite cell lines in vitro [9]. In low-calcium, serum-free medium, NHU cells adopt a rapidly-
proliferating, non-differentiated regenerative phenotype [10] driven by autocrine EGFR 
signalling [11]. In vitro-propagated NHU cell lines retain differentiation capacity and can 
be induced to stratify [10], express genes associated with late/terminal urothelial 
cytodifferentiation [12] and form a functional, barrier-epithelium [13].  The genetic 
manipulation of NHU cells with retroviruses has enabled the generation of “para-
malignant” [14] human urothelial sub-lines carrying defined genetic alterations, such as 
inactivated p53 or p16 functions [15-17]. We have shown that tumour suppressor 
inactivation has differential effects on NHU cell responses to genotoxic damage or non-
genotoxic pro-apoptotic signals [16] and in modulating sensitivity to inhibitors of growth-
promoting pathways [17].   
 
In this study, we have used para-malignant human urothelial cells to investigate how 
defined genetic alterations associated with carcinogenesis affect not only proliferation and 
life-span, but also capacity for cytodifferentiation and barrier formation.  Alongside 
previously-generated p53 and p16 functional knock-out cells, we have engineered 
urothelial cells with constitutively-activated mutant FGFR3 or over-expression of hTERT. 
Differentiated urothelial barrier function is contributed to by both paracellular barrier 
function (attributed to tight junctions) and trans-cellular barrier function (contributed to by 
the uroplakins, UPKs).  Of the uroplakins, UPK2 and UPK3a represent the two most highly-
restricted late/terminal differentiation stage and urothelium-specific markers available 
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[18].  Here, we have assessed both functional and molecular aspects of differentiation by 
investigating the ability of transduced cells to generate a functional tight barrier and to 
express uroplakin transcripts.     
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Materials and Methods 
 
Cell culture  
NHU cell cultures established from urological specimens obtained with informed consent 
from patients with no UC history were maintained as finite cell lines as detailed elsewhere 
[9,10].  
 
Retrovirus preparation and transduction 
Wild-type FGFR3 (FGFR3WT) and FGFR3S249C mutant (FGFR3mut) sequences (Dr Francois 
Radvanyi, Institut Curie, France) were PCR-amplified to incorporate EcoRI/BamHI for sub-
cloning into pLXSP, thus generating pLXSP-FGFR3WT and pLXSP-FGFR3mut, respectively.  
The pLXSP vector was derived from pLXSN (Clontech) by replacing the neomycin 
resistance gene with a puromycin expression sequence, as detailed elsewhere [16]. hTERT 
cDNA (Dr Jerry Shay, Southwestern Medical Center, USA) was sub-cloned into the EcoRI 
site of pLXSN, thus generating pLXSN-hTERT.  
 
Retrovirus transductions were performed as described [16]. PT67 fibroblasts (Clontech) 
were transfected with pLXSN-hTERT, pLXSN-p53DD, pLXSP-CDK4R24C [16], pLXSP-
FGFR3WT or pLXSP-FGFR3mut, as well as pLXSN and pLXSP vectors. Three independent 
NHU lines were transduced with control or recombinant retroviruses resulting in control 
(HU-neo/HU-puro) and para-malignant (HU-hTERT, HU-p53DD, HU-CDK4mut, HU-
FGFR3WT and HU-FGFR3mut) sub-lines. Immortalised, post-crisis HU-E6P cells were 
derived from NHU cells transduced with human papillomavirus 16 E6 oncoprotein as 
previously described [15].   
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Comparative genomic hybridisation (CGH) arrays 
CGH was carried out using Homo sapiens AROS v4.0 OpArrays (Operon Biotechnologies) 
and analysed using ArrayAssist Expression software v5.5 (Stratagene). A list of 3439 genes 
was generated and imported into CGH-Explorer (v2.5) software [19] for copy number 
analysis.  
 
Immunoblotting   
Immunoblotting was performed as described [16] with the following primary antibodies: 
rabbit anti-phospho-ERK (#9101, Autogen Bioclear), mouse anti-panERK (clone#16, BD 
Biosciences), rabbit anti-FGFR3 (B-9; Autogen Bioclear), rabbit anti-FOXA1 (D-20; Autogen 
Bioclear), mouse anti-PPARγ (E8, Autogen Bioclear) and mouse anti-β-actin (KJ43A, 
Sigma-Aldrich).  Secondary antibodies were goat anti-rabbit immunoglobulin conjugated 
with IRDye® 800 (Tebu-Bio) or anti-mouse immunoglobulin conjugated with Alexa Fluor® 
680 (Invitrogen). Immunoblots were analysed on a Li-Cor Odyssey (Cambridge).  
 
Telomerase  
Telomerase activity was measured using a TRAPeze XL telomerase detection kit 
(Millipore).  For immunocytochemistry, anti-hTERT antibody (rabbit polyclonal, #600-401-
252, Rockland Immunochemicals) was followed by goat anti-rabbit immunoglobulin 
conjugated to Alexa Fluor® 488 (Invitrogen).  
 
Urothelial cytodifferentiation 
Urothelial cells were induced to differentiate by co-activation of PPARγ and inhibition of 
EGFR signalling as described [12,20,21]. RNA was isolated, cDNA synthesised and real-
time PCR performed using TaqMan™ PCR primers with UPK2, UPK3a and GAPDH probes 
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[22]. Data were analysed using ABI Prism 7700 SDS software (Applied Biosystems) and 
normalised against GAPDH (internal control).  
 
Development and assessment of barrier function 
Transepithelial electrical resistance (TER) was measured by electrophysiology. Urothelial 
cells were grown in KSFMc containing 5% (v/v) adult bovine serum (ABS) before sub-
culture onto Snapwell™ membranes. TER measurements were made as described [13].    
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Results 
Verification of para-malignant cell lines  
Immunoblotting corroborated transgene expression in HU-FGFR3WT and HU-FGFR3mut 
cells, with control HU-puro cells showing little FGFR3 expression (Figure 1A). 
HU-FGFR3WT and HU-FGFR3mut expressed higher basal p-ERK levels than controls 
(Figure 1B); addition of FGF1 did not further increase phosphorylation. Treatment with 
EGFR inhibitor (PD153035) blocked ERK-phosphorylation in HU-puro and HU-FGFR3 cells, 
yet only weakly down-modulated p-ERK in HU-FGFR3mut (Figure 1B). Exposure to FGF1 in 
PD153035-treated HU-FGFR3WT, but not PD153035-treated HU-puro cells, rescued p-ERK 
levels, whilst FGF1 treatment did not further increase p-ERK expression in HU-FGFR3mut 
cells (Figure 1 and supplementary Figure 1). This confirmed the ligand-independent, 
constitutively-activated status of the FGFR3mut construct and the ligand-dependent 
functionality of FGFR3WT.  
  
Immunofluorescence microscopy confirmed increased expression of nuclear hTERT in HU-
hTERT cells over HU-neo controls (Figure 1C). The demonstration of endogenous/basal 
hTERT by NHU cells was in agreement with previous reports [23]. hTERT activity was also 
confirmed by assaying telomerase activity (Table 1). HU-hTERT cells at different passages 
(see Table 1) consistently showed several-fold higher telomerase activity than HU-neo 
cells.    
 
Effect of cancer gene transduction on proliferation and lifespan 
We have previously reported that neither loss of p53 nor p16 alone caused an extension in 
NHU lifespan [16]. Similarly, over-expression of neither wild-type FGFR3 protein nor the 
constitutively-activated FGFR3 mutant had any effect on lifespan (not shown). Although 
isogenic HU-neo could only be cultured to p9-p10 before senescence, HU-hTERT cells 
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continued to proliferate until approximately p12 (Figure 2A). At this point, cells exhibited a 
lag-phase, characterised by reduced growth rates, but there was neither visible mass 
death nor signs of clonal recovery (Figure 2B). The lag-phase lasted from p11-p13, but by 
p15, HU-hTERT populations had resumed normal proliferation rates and were 
morphologically-similar to normal NHU cultures, showing regular epithelioid morphology. 
By p20, cells began to show subtle morphological changes and appeared heterogeneous, 
with a proportion of cells being of smaller size.  Upon repeated sub-culture, and despite no 
changes in proliferation rates, HU-hTERT cells progressively adopted a smaller-size 
phenotype, which remains the same to date (>p45).  These findings were reproducible 
with cells recovered from cryopreservation at different passages and indicate that over-
expression of hTERT alone can efficiently immortalise NHU cells.   
Coinciding with the lag in growth, expression of the cyclin-dependent kinase inhibitory p16 
protein increased in hTERT-transduced cells up to passage 12, and reduced in later sub-
cultures (Figure 3).   
 
Genomic analysis of hTERT-immortalised cells 
To exclude the possibility that the extension of NHU cell lifespan was due to accumulation 
of genetic changes and/or abnormalities, such as those reported for HPV16 E6-transduced 
cells [15], CGH arrays were used to assess the genomic integrity of HU-hTERT cells. When 
cells at p7 and p40 were compared, no significant alterations were seen across the 
genome (Figure 4 and supplementary data), including the frequently-modified regions of 
chromosomes 3p, 9q, 8q and 20 (reviewed in [14]). This absence of karyotypic alterations 
agrees with other reports [24].   
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Effect of para-malignant changes on differentiation capacity 
Combined treatment of NHU cells with PD153035 (EGFR antagonist) and troglitazone (TZ, 
PPARγ ligand) induces a programme of gene expression changes associated with terminal 
differentiation; this is mediated via the PPARγ-dependent transcription of intermediary 
transcription factors, including FOX-A1 [21].  When tested within the lifespan of the 
isogenic lines, sub-lines transduced with hTERT, mutant or wild type FGFR3, p16-
insensitive CDK4 mutant or dominant-negative p53, all responded to treatment with 
PD153035 and TZ by induction of UPK2 transcript expression (Figure 5); no attenuation of 
signal was seen compared to isogenic plasmid-only controls. By contrast, UPK2 expression 
was not induced in post-crisis HU-E6P cell cultures (Figure 5).     
 
The response of HU-hTERT cells to TZ/PD153035 treatment was assessed over a range of 
passages.  Although HU-hTERT cells were induced to express UPK2 and UPK3a transcripts 
at p10 (i.e. within the normal lifespan), by p17 the response was severely attenuated, as 
HU-hTERT cells showed only baseline UPK2 (Figure 7A) and UPK3a (Supplementary Figure 
2) expression.  Further examination revealed that although PPARγ expression was 
retained, the responsiveness of cells to PPARγ activation was curtailed, with FOX-A1 
induction reduced by >50% in both HU-hTERT cells and post-crisis HU-E6P cells (Figure 
7B).  
 
Effect of para-malignant changes on urothelial barrier function  
Sub-culture of NHU cells in medium containing serum and 2mM calcium stimulates them to 
stratify and develop functional barrier properties equivalent to normal urothelia [13]. We 
examined the ability of para-malignant cell lines to form a tight barrier, as assessed by 
measurement of trans-epithelial resistance (TER).  
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Under normal growth conditions, all cultures showed limited TER (<50 Ω.cm2). Within the 
normal lifespan, all para-malignant sub-lines responded to the serum/calcium protocol by 
formation of urothelial sheets with tight barrier properties; no significant differences were 
noted against the respective vector-only controls (Figure 6, panels A, B and C). By 
contrast, transformed HU-E6P cells failed to form a substantial barrier (Figure 6B).  
 
When the ability of late-passage HU-hTERT to form a barrier was examined and, in 
accordance with UPK2 and UPK3a expression, we found that cells up to p10 were able to 
form a tight barrier with equivalent TER to non-transformed control cultures (Figure 7C). 
HU-hTERT cells produced a partial barrier at p17 and p28, and showed no barrier 
formation at p41, where TER values were similar to those of non-differentiated control 
cultures (Figure 7C).  
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Discussion  
NHU cells with abrogated p53 (but not p16) function exhibited increased growth rates and 
reduced dependency on EGFR-driven proliferation [17], whereas p16 (but not p53) 
inactivation altered urothelial cell responses to pro-apoptotic signals [16].  We now show 
that neither loss of p53 nor p16 function had any direct effect on differentiation, in 
agreement with the normal differentiation potential of keratinocytes with inactivated p16 
function [25]. Less expected was the lack of any association between loss of p53 and 
differentiation, as changes in p53 have been associated with carcinoma in situ [5], thus 
implying that other changes may contribute to the dysplastic phenotype.    
 
FGFR3 mutation is closely-associated with benign urothelial hyperplasia [3]. Due to the 
low-grade nature of these tumours, it was not unexpected that HU-FGFR3mut cells 
showed no loss of differentiation capacity. Although mutant-FGFR3 had no overt effect on 
NHU proliferation despite an increase in ERK phosphorylation, it is likely that FGFR3mut-
mediated proliferation signals would be masked, as NHU cultures are already in a high-
proliferation state driven by autocrine/paracrine EGFR/ERK signalling [11,17]. Indeed, 
functional EGFR-blocking suggested cross-talk downstream of FGFR3 and EGFR signalling 
through ERK. Thus, FGFR3-driven ERK activation may contribute to tumour growth in vivo.  
 
It is striking that, unlike inactivation of p53 or p16, hTERT over-expression alone could 
influence both the lifespan and differentiation potential of urothelial cells. Our findings are 
in agreement with a previous report demonstrating hTERT-mediated immortalisation of 
NHU cells [24]. In accordance with our study, Chapman et al. reported that 
immortalisation of NHU cells was not accompanied by any detectable genetic instability 
when the HU-hTERT derivatives were maintained under conditions optimised for the 
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culture of NHU cells, although they did observe a predisposition to genetic aberration 
when hTERT over-expressers were stressed under sub-optimal culture conditions [26].  
 
Several epithelial types have been immortalised by hTERT, but this often requires 
concurrent inactivation of tumour suppressor function [27,28].  As shown in this study and 
reported elsewhere [24], urothelial cells, in common with prostate and small airway 
epithelial cells [29,30], were immortalised by hTERT over-expression alone.  Prior to 
immortalisation, HU-hTERT populations displayed a lag-phase (p11-p13) characterised by 
reduced growth rates, without senescence or apoptosis. Importantly, there was no 
emergence of a rare, rapidly-growing cell population that would have indicated clonal 
recovery.  Accumulation of p16 has been associated with urothelial senescence in culture 
and is recognised as an essential block to neoplastic transformation [25].  In agreement 
with this and observations by Chapman et al [24], we saw a dramatic increase in p16 
protein associated with the growth lag around the normal senescence point at passage 12 
and growth rate recovery was accompanied by a reduction in p16 expression. In the 
absence of genomic aberration, these observations fit a scenario in which p16 gene 
expression is silenced epigenetically, as shown for small airway epithelial cells [30].  
However, p16 silencing does not provide a complete mechanism, as we have shown 
previously that direct abrogation of p16 function does not overcome senescence and is not 
immortalising in NHU cells [16].  
 
Proliferating NHU cells express (low level) endogenous hTERT expression, as shown in this 
study (Figure 1C) and elsewhere [23], as do some somatic cell types that have the 
capacity to switch from a quiescent to highly-proliferative phenotype. Urothelium is 
renowned as a low-turnover, mitotically-quiescent epithelium that has high regenerative 
capacity. With its ability to overcome proliferation constraints and block differentiation, 
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hTERT may facilitate tumorigenesis by promoting proliferation over differentiation, thus 
“priming” cells for a second-hit to a loss-of-function senescence block, although 
appropriate in vivo studies would be necessary to address this hypothesis. Our findings 
support the reported association of hTERT over-activation and bladder cancer [7] and 
provide a basis for explaining the grade/stage relationship.  
 
Although the precise underlying mechanisms for this remain unclear, hTERT over-
expression can progressively attenuate the molecular differentiation of NHU cells (shown 
in this study and reported elsewhere [31]) and diminish their capacity to form a functional 
urothelial barrier.  A mechanism for hTERT-mediated suppression of differentiation would 
be in keeping with the stem cell maintenance function of hTERT, whose activity is known 
to extend beyond telomerase activation and includes chromatin reorganisation, indicating 
a potential role in epigenetic regulation of gene transcription [32].  The loss of 
differentiation capacity by hTERT-immortalised urothelial cells implies that immortalisation 
by hTERT and the loss of differentiation capacity are causally-linked. A likely scenario is 
that the hTERT-mediated chromatin reorganisation affects the efficacy of ligand-activated 
PPARγ, as a nuclear receptor, to bind and initiate the cascade of transcriptional and 
chromatin reorganising events associated with urothelial differentiation. Further studies in 
this area of epigenetic regulation are likely to provide novel insight into the cancer 
evolution process.  
 
 
Conclusions  
Immortalised, cytogenetically-normal HU-hTERT cells should provide a valuable resource 
by overcoming some of the problems of working with NHU lines of finite lifespan. 
However, HU-hTERT cells can no longer be regarded as “normal” and cannot be 
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substituted in studies where normal regulatory controls are assumed. This may limit their 
application, although they nevertheless provide a valuable model for clarifying the role of 
telomerase activation in UC and its influence on proliferation and differentiation.   
  
 
Acknowledgements  
We are grateful to clinical colleagues for tissue samples. W Cross and R Duke are 
acknowledged for contributions to experiments. NTG was funded by EPSRC 
(GR/S62338/01). LC, CLV and JS are supported by York Against Cancer.   
 
Georgopoulos et al     Page 18 of 27 
  
 
 
References  
 
[1] Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005; 
5: 713-25. 
[2] Harnden P and Parkinson MC. Transitional cell carcinoma of the bladder: diagnosis and 
prognosis. Current Diagnostic Pathology. 1996; 3: 109-121. 
[3] Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M et al. 
Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA 
samples complements cytology in bladder tumor detection. Cancer. 2003; 98: 737-44. 
[4] Hart KC, Robertson SC and Donoghue DJ. Identification of tyrosine residues in 
constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat 
activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell. 2001; 12: 931-42. 
[5] Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T and Cordon-Cardo 
C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 
2010; 28: 401-8. 
[6] Shay JW and Bacchetti S. A survey of telomerase activity in human cancer. Eur J 
Cancer. 1997; 33: 787-91. 
[7] Orlando C, Gelmini S, Selli C and Pazzagli M. Telomerase in urological malignancy. J 
Urol. 2001; 166: 666-73. 
[8] Shay JW. Telomerase therapeutics: telomeres recognized as a DNA damage signal: 
commentary re: K. Kraemer et al., antisense-mediated hTERT inhibition specifically 
reduces the growth of human bladder cancer cells. Clin. Cancer Res., 9: 3794-3800, 2003. 
Clin Cancer Res. 2003; 9: 3521-5. 
Georgopoulos et al     Page 19 of 27 
  
 
[9] Southgate J, Masters JR and Trejdosiewicz LK: Culture of Human Urothelium, in 
Freshney RIaF, M.G. (eds.): Culture of Epithelial Cells. New York, J Wiley and Sons, Inc., 
2002, pp 381-400. 
[10] Southgate J, Hutton KA, Thomas DF and Trejdosiewicz LK. Normal human urothelial 
cells in vitro: proliferation and induction of stratification. Lab Invest. 1994; 71: 583-94. 
[11] Varley C, Hill G, Pellegrin S, Shaw NJ, Selby PJ, Trejdosiewicz LK et al. Autocrine 
regulation of human urothelial cell proliferation and migration during regenerative 
responses in vitro. Exp Cell Res. 2005; 306: 216-29. 
[12] Varley CL, Stahlschmidt J, Lee WC, Holder J, Diggle C, Selby PJ et al. Role of 
PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J 
Cell Sci. 2004; 117: 2029-36. 
[13] Cross WR, Eardley I, Leese HJ and Southgate J. A biomimetic tissue from cultured 
normal human urothelial cells: analysis of physiological function. Am J Physiol Renal 
Physiol. 2005; 289: F459-68. 
[14] Crallan RA, Georgopoulos NT and Southgate J. Experimental models of human 
bladder carcinogenesis. Carcinogenesis. 2006; 27: 374-81. 
[15] Diggle CP, Pitt E, Harnden P, Trejdosiewicz LK and Southgate J. Role of p53 in the 
responses of human urothelial cells to genotoxic damage. Int J Cancer. 2001; 93: 199-
203. 
[16] Shaw NJ, Georgopoulos NT, Southgate J and Trejdosiewicz LK. Effects of loss of p53 
and p16 function on life span and survival of human urothelial cells. Int J Cancer. 2005; 
116: 634-9. 
[17] MacLaine NJ, Wood MD, Holder JC, Rees RW and Southgate J. Sensitivity of normal, 
paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth 
factor receptor signaling pathway. Mol Cancer Res. 2008; 6: 53-63. 
Georgopoulos et al     Page 20 of 27 
  
 
[18] Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G et al. Uroplakin gene 
expression in normal human tissues and locally advanced bladder cancer. J Pathol. 2003; 
199: 41-9. 
[19] Lingjaerde OC, Baumbusch LO, Liestol K, Glad IK and Borresen-Dale AL. CGH-
Explorer: a program for analysis of array-CGH data. Bioinformatics. 2005; 21: 821-2. 
[20] Varley CL, Garthwaite MA, Cross W, Hinley J, Trejdosiewicz LK and Southgate J. 
PPARgamma-regulated tight junction development during human urothelial 
cytodifferentiation. J Cell Physiol. 2006; 208: 407-17. 
[21] Varley CL, Bacon EJ, Holder JC and Southgate J. FOXA1 and IRF-1 intermediary 
transcriptional regulators of PPARgamma-induced urothelial cytodifferentiation. Cell Death 
Differ. 2009; 16: 103-14. 
[22] Southgate J, Varley CL, Garthwaite MA, Hinley J, Marsh F, Stahlschmidt J et al. 
Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU 
Int. 2007; 99: 1506-16. 
[23] Belair CD, Yeager TR, Lopez PM and Reznikoff CA. Telomerase activity: a biomarker 
of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A. 1997; 94: 
13677-82. 
[24] Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS and Knowles MA. Expression 
of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb 
pathway. Oncogene. 2006; 25: 5037-45. 
[25] Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H et al. A two-stage, 
p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits 
replicative potential independent of telomere status. Mol Cell Biol. 2002; 22: 5157-72. 
[26] Chapman EJ, Williams SV, Platt FM, Hurst CD, Chambers P, Roberts P et al. 
Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-
Georgopoulos et al     Page 21 of 27 
  
 
immortalized urothelial cells (TERT-NHUC). Genes Chromosomes Cancer. 2009; 48: 694-
710. 
[27] Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA et al. Human 
keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that 
limits life span become immortal yet retain normal growth and differentiation 
characteristics. Mol Cell Biol. 2000; 20: 1436-47. 
[28] Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC, Jr. et al. 
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is 
sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis. 
2007; 28: 174-82. 
[29] Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G et al. hTERT-
immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for 
differentiation and carcinogenesis. Cancer Res. 2006; 66: 3531-40. 
[30] Piao CQ, Liu L, Zhao YL, Balajee AS, Suzuki M and Hei TK. Immortalization of human 
small airway epithelial cells by ectopic expression of telomerase. Carcinogenesis. 2005; 26: 
725-31. 
[31] Chapman EJ, Kelly G and Knowles MA. Genes involved in differentiation, stem cell 
renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial 
cells. Mol Cancer Res. 2008; 6: 1154-68. 
[32] Cong Y and Shay JW. Actions of human telomerase beyond telomeres. Cell Res. 
2008; 18: 725-32. 
 
 
 
 
 
 
 
Georgopoulos et al     Page 22 of 27 
  
 
Table 1 Measurement of telomerase activity in transduced NHU cells 
 
 
 
 
Cell Line *Telomerase activity  
(relative to HU-neo) 
HU-neo  
HU-hTERT at p9 
HU-hTERT at p16 
HU-E6P  
HU-neo (heat inactivated) 
HU-hTERT at p9 (heat inactivated) 
HU-hTERT at p16 (heat inactivated) 
HU-E6P (heat inactivated) 
1.0 ± 0 
3.0 ± 0.2 
3.5 ± 0.1 
19.2 ± 8.2 
-0.2 ± 0 
-0.4 ± 0.2 
0.0 ± 0.4 
-0.2 ± 0 
 
 
Cell lysates were prepared and PCR performed according to the manufacturer’s 
instructions, using the reaction profile of 30 min at 30oC, followed by 36 cycles of 30 s at 
94oC, 30 s at 59oC and 1 min at 72oC. Following PCR, fluorimetric measurements were 
made at 495nm (telomerase activity) and 600nm (sulforhodamine internal control). 
Following background subtraction for each channel to determine net fluorescein (FL) and 
sulforhodamine (R), telomerase activity in HU-hTERT was expressed as the ratio of FL/R 
and normalised against the HU-neo signal (*).  Immortalised HU-E6P cells were included 
as positive controls and heat-inactivated samples served as negative controls. Values are 
means of triplicate samples (±standard deviation, SD) and are representative of two 
independent experiments.   
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Figure Legends 
 
Figure 1 Verification of functional FGFR3 and hTERT over-expression  
(A) Human urothelial cells over-expressing wild-type (HU-FGFR3WT), constitutively-
activated mutant FGFR3 (HU-FGFR3mut) and empty virus (control) cells (HU-puro) were 
established by retroviral transduction. To confirm transgene expression, cell lysates were 
prepared and FGFR3 expression assessed by SDS-PAGE and immunoblotting. Alongside 
untreated controls, replicate cultures were maintained in medium containing 1µM EGFR 
inhibitor PD153035 for 24 hours, followed by treatment with or without 1nM FGF1 ligand 
(FGF1) in 2µg/mL heparin for a further 24 hours.  
(B) Urothelial cells were treated as above and expression of phosphorylated ERK (p-
ERK1/2) protein was assessed by SDS-PAGE and immunoblotting using a rabbit polyclonal 
antibody. To ensure equal loading, membranes were simultaneously probed with a mouse 
monoclonal antibody for detection of total ERK. This was followed by treatment with 
fluorochrome-conjugated goat anti-rabbit antibody (green) and anti-mouse (red) 
antibodies, respectively, and immunolabelling was visualised by infrared imaging as 
described in the Methods section. The relative expression of pERK2 was calculated from 
the densitometry readings and is stated below each track (representative of two 
experiments). 
(C) Expression of the catalytic unit of telomerase (hTERT) was assessed in isogenic control 
(HU-neo) and hTERT over-expressers (HU-hTERT) cells by indirect immunofluorescence 
microscopy. Urothelial cells were fixed, permeabilised and labelled with primary anti-
hTERT antibody followed by Alexa Fluor 488-conjugated secondary antibody; nuclei were 
visualised using Hoechst 33258.  Scale bar: 50µM. 
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Figure 2 Effects of long-term hTERT over-expression on urothelial cell 
morphology and growth  
(A) Retrovirus-transduced control (HU-neo) and over-expressing hTERT (HU-hTERT) cells 
were cultured in standard culture medium (KSFMc) and representative phase contrast 
micrographs taken at various passage numbers. For HU-neo: a) p5, b) p10. For HU-
hTERT: i) p5, ii) p10, iii) p11, iv) p12, v) p13, vi) p15, vii) p20, viii) p30. Scale bar: 50µM. 
(B) HU-hTERT cells were maintained as above and consistently sub-cultured upon 
reaching confluency at a 1:3 ratio. The passage number of HU-hTERT cultures was 
recorded over a total sequential culture period of 299 days (40 passages) and thus the 
graph is representative of the time-length between each passage. The labels (i-viii) 
correspond to the passages where the representative images in (A) were taken.     
 
Figure 3 The effect of long term culture on p16 protein expression in 
HU-hTERT cells 
Protein lysates were prepared from HU- hTERT cells at passage 6, 12, 15 and 27.  
A) p16 protein expression was assessed by immunoblotting with a p16 mouse monoclonal 
antibody and compared to isogenic control (HU-neo) at passage 6. To ensure equal 
loading, membranes were also probed with an antibody to β-actin.   
B) Densitometry readings for p16 were normalised to β-actin and displayed as a bar 
graph. 
 
Figure 4 Effects of hTERT expression on urothelial cell karyotype  
Genomic DNA was isolated from HU-hTERT cultures at p7 and p40 and comparative 
genomic hybridisation (CGH) was carried out as detailed in the Methods. The generated 
data was filtered for background correction and subsequently normalised by mean scale 
normalisation using the ArrayAssist Expression software. The list of genes from the above 
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analysis was generated with expression ratios of sample1/sample2.  The generated list, 
including gene identities, chromosome number and location was imported into the CGH-
Explorer software for copy number analysis (see supplementary data).  
 
Figure 5 Assessment of differentiation potential of transduced NHU 
sub-lines   
NHU-derived sub-lines HU-FGFR3WT, HU-FGFR3mut, HU-p53DD, HU-CDK4mut and HU-
hTERT, alongside control cell lines HU-neo and HU-puro (all at <p7) and post-crisis, 
immortalised HU-E6P cells were induced to differentiate by treatment with 1µM 
troglitazone (TZ) and 1µM PD153035 (PD) in combination (TZ+PD). DMSO controls (Con) 
were also included. RNA was extracted, cDNA generated and quantitative PCR was 
performed.  UPK2 expression values were initially normalized relatively to those of the 
internal control (GAPDH) to calculate relative UPK2 expression. Results were then 
expressed as fold UPK2 expression with respect to isogenic untransduced NHU controls. 
Each bar thus represents mean fold UPK2 expression (±SD) of three replicates for one 
representative cell line for each transduction.  
 
Figure 6 Assessment of barrier function capacity of transduced NHU 
sublines 
Transduced control cell lines HU-neo and HU-puro, and para-malignant sub-lines HU-
FGFR3WT, HU-FGFR3mut (A), HU-hTERT and post-crisis, immortalised HU-E6P (B), as well 
as HU-p53DD and HU-CDK4mut cells (C) (all at <p7) were grown on Snapwell™ chambers 
in the presence of 5% ABS and 2mM Ca2+, and trans-epithelial electrical resistance (TER) 
was measured (as detailed in the Methods). Bar graphs represent mean TER value (±SD) 
of three replicate samples following background subtraction.  
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Figure 7 Effects of long-term hTERT over-expression on molecular 
differentiation and barrier function of urothelial cell cultures 
(A) Control virus-transduced (HU-neo) and HU-hTERT cells at the indicated passage 
number were induced to undergo differentiation following treatment with combination of 
1µM PPARγ agonist troglitazone and 1µM EGFR inhibitor PD153035 (TZ+PD). Total RNA 
was extracted, cDNA generated and quantitative real-time RT-PCR was performed to 
assess UPK2 mRNA expression. For each datum point, UPK2 mRNA level was normalised 
relative to that for the internal control (GAPDH) and each bar represents mean 
UPK2/GAPDH ratio (±SD) for three replicates. 
(B) HU-neo (p7), late-passage HU-hTERT (p23) and HU-E6P cells were exposed to DMSO 
vehicle control (-) or treated with TZ+PD (+) as described above and expression of PPARγ 
and FOXA1 were assessed by immunoblotting.  Densitometry values for the relevant 
protein bands are indicated, following normalisation against β-actin.    
(C) Control (HU-neo) cells, HPV16 E6-expressing (HU-E6P) derivatives and hTERT over-
expressers (HU-hTERT) at the indicated passage numbers were treated with medium 
containing 5% serum in the presence of 2mM Ca2+ (ABS+Ca) for induction of 
differentiation and trans-epithelial resistance assays were performed. Untreated, non-
differentiated, isogenic HU-neo cells (ND Con) were included as negative controls. Bars 
represent mean TER value (±SD) of three replicate samples for each cell line following 
background subtraction.  
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Supplementary Figure 1  
Effect of FGF1 and EGFR inhibitor PD153035 on ERK1/2 phosphorylation 
in human urothelial cells over-expressing wild-type (HU-FGFR3WT), 
constitutively-activated mutant FGFR3 (HU-FGFR3mut) and empty virus 
(control) cells (HU-puro).   
Cell lysates were prepared after 24h treatment with or without PD153035 (1 µM) or FGF1 
(1 nM) and phosphorylated ERK (p-ERK1/2) protein was assessed by SDS-PAGE and 
immunoblotting using a rabbit polyclonal antibody.  To ensure equal loading, membranes 
were simultaneously probed with a mouse monoclonal antibody for detection of total ERK. 
This was followed by treatment with fluorochrome-conjugated goat anti-rabbit antibody 
(green) and anti-mouse (red) antibodies, respectively, and immunolabelling was visualised 
by infrared imaging as described in the Methods section.   
 
Supplementary Figure 2  
Effects of long-term hTERT over-expression on UPK3a expression.  
Control virus-transduced (HU-neo) and HU-hTERT cells at the indicated passage number 
were induced to undergo differentiation following treatment with combination of 1µM 
PPARγ agonist troglitazone and 1µM EGFR inhibitor PD153035 (TZ+PD). Total RNA was 
extracted, cDNA generated and quantitative real-time RT-PCR was performed to assess 
UPK3a mRNA expression. For each datum point, UPK3a mRNA level was normalized 
relative to that for the internal control (GAPDH) and each bar represents mean 
UPK3a/GAPDH ratio (±SD) for three replicates.  
 
 
 
 
